Given the observed co-activation of JAK2 and TrkA in triple-negative and HER2-enriched breast cancers, we speculate that co-targeting of JAK2 and TrkA would be a promising new therapeutic modality against breast cancer. Here, ERBB2 is linked to breast carcinoma.